EICHORCondition: Recurrent Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7 · Sponsor: National Cancer Institute (NCI)
This randomized phase II trial studies how well trametinib with or without Akt inhibitor GSK2141795 (GSK2141795) works in treating patients with uveal melanoma that has spread to other parts of the body (metastatic). Trametinib and GSK2141795 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective with or without GSK2141795 in treating patients with metastatic uveal melanoma.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Emory University Hospital/Winship Cancer Institute | Atlanta, Georgia, United States | — |
| NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York, New York, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| Vanderbilt University/Ingram Cancer Center | Nashville, Tennessee, United States | — |
| UT MD Anderson Cancer Center | Houston, Texas, United States | — |
| Institut Curie Paris | Paris, France | — |
| The University of Liverpool | Liverpool, United Kingdom | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01979523